Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine Stellate Ganglion Blockade for Preventing POAF After CABG
NCT07570940Phase 4Not yet recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Atrial fibrillation (AFib) comparing Stellate ganglion block using liposomal bupivacaine with Sham block using saline placebo (2 arms). Primary endpoint: Incidence of new-onset postoperative atrial fibrillation at 1 week. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
liposomal bupivacaine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07570940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570940.